Trius to Present at the BioCentury Future Leaders Conference

Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation on Friday April 20, 2012 at 9:30 a.m

San Diego, CA (prHWY.com) April 17, 2012 - SAN DIEGO, April 17, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation on Friday April 20, 2012 at 9:30 a.m. Eastern Time at the 19th annual Future Leaders in the Biotech Industry investment conference at the Millennium Broadway Hotel in New York.

About Trius Therapeutics
Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. The Company's lead investigational drug, tedizolid phosphate, is a once daily, IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of ABSSSI. Trius has two Special Protocol Assessments with the FDA for its two Phase 3 ABSSSI trials and has partnered with Bayer HealthCare for the development and commercialization of tedizolid phosphate outside of the U.S., Canada and the European Union. In addition to the Company's tedizolid phosphate clinical program, Trius has initiated IND-enabling studies for its Gyrase-B development candidate with potent activity against Gram-negative bacterial pathogens including multi-drug resistant strains of E. coli, Klebsiella, Acinetobacter and Pseudomonas. The Gyrase-B program is one of the three preclinical programs supported by federal contracts. For more information, visit www.triusrx.com.

###

Tag Words: gyraseb, bayer healthcare, biopharmaceutical

Categories: Health

Press Release Contact
Public Relations Contact:
Jason Spark at Canale Communications, Inc.
6310 Nancy Ridge Drive
Suite 101
San Diego, CA 92121
jason@canalecomm.com
619-849-6005

Link To This Press Release:

URL HTML Code